Related Experiment Video
Updated: Oct 22, 2025
10:11
Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
36.6K
Therapeutics development for Ebola virus disease: A recent scenario
1Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Barasat-Barrackpore Rd, Kolkata, West Bengal, 700126, India.
Current Opinion in Pharmacology
|August 31, 2021
Summary
Ebola virus disease (EVD) is a severe illness with a high fatality rate. Current therapeutic developments include small-molecule inhibitors, RNA interference, and antibody treatments, with two monoclonal antibodies now FDA-approved.
Area of Science:
- Virology
- Infectious Diseases
- Drug Development
Background:
- Ebola virus disease (EVD) is a severe, often fatal illness caused by the Ebola virus, characterized by a high case-fatality rate.
- Four species of the Ebola virus—Ebola, Taï Forest, Sudan, and Bundibugyo—are known to cause disease in humans.
Purpose of the Study:
- To provide a comprehensive overview of the therapeutic landscape for Ebola virus disease.
- To illustrate the developmental strategies for various therapeutic approaches against EVD.
Main Methods:
- Review of therapeutic development for EVD, including small-molecule inhibitors, small interfering RNAs, antibodies, ion channel inhibitors, interferons, and combination therapies.
- Analysis of clinical trial outcomes, specifically the Pamoja tuLinde Maisha trial for monoclonal antibodies.
Main Results:
- Two monoclonal antibodies, REGN-EB3 and mAb114, demonstrated significant efficacy in clinical trials.
- These two monoclonal antibodies have received approval from the United States Food and Drug Administration (FDA).
Conclusions:
- Significant progress has been made in EVD therapeutics, with approved antibody treatments available.
- Future research should prioritize the development of more economically viable treatment options for EVD.
